Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.47 |
| ▸ | HTR2A | P28223 | 4/20 | 0.47 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 3/20 | 0.46 |
| ▸ | HTR3A | P46098 | 4/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL906086 | 0.88 | PRMT5 (0.48) | HTR2CHTR2AHTR1AALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL11603074 | 0.77 | HTR1A (0.50) | HTR2CHTR2AHTR1AALDH1A1CYP1A2 | |
| SCHEMBL906142 | 0.77 | HTR2C (0.63) | HTR2CHTR2AHTR1AALDH1A1CYP1A2 | |
| SCHEMBL3266333 | 0.77 | HTR2C (0.59) | HTR2CHTR2AHTR1AALDH1A1CYP1A2 | |
| SCHEMBL3267894 | 0.76 | HTR2C (0.71) | HTR2CHTR2AHTR1AALDH1A1CYP1A2 | |
| SCHEMBL3267269 | 0.76 | TAAR1 (0.54) | HTR2CHTR2AHTR1AALDH1A1CYP1A2 | |
| SCHEMBL3267745 | 0.75 | ACHE (0.58) | HTR2CHTR2AHTR1AALDH1A1CYP1A2 | |
| SCHEMBL27534548 | 0.73 | PIM2 (0.48) | HTR2CHTR2AHTR1AALDH1A1CYP1A2 | |
| SCHEMBL906114 | 0.73 | HTR2C (0.74) | HTR2CHTR2AHTR1AALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL11605186 | 0.72 | HTR2C (0.57) | HTR2CHTR2AHTR1AALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335907-B1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB PUBL (SE) | 2010-06-09 | — | — | EP | claimed |
| CN-1267424-C | Piperazinylpyrazine compounds as agonists or antagonists of the 5-hydroxytryptamine 5 HT-2 receptor | BIOVITRUM AB (SE) | 2006-08-02 | — | — | CN | claimed |
| CN-1479727-A | Piperazinylpyrazine compounds as agonists or antagonists of the 5-hydroxytryptamine 5 HT-2 receptor | �Ȱ�ά����ķ�ɷݹ�˾ | 2004-03-03 | — | — | CN | claimed |
| EP-1335907-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2003-08-20 | — | — | EP | claimed |
| US-6593330-B2 | Central nervous system disorders; antiserotonine agents | BIOVITRUM (SE) | 2003-07-15 | — | — | US | claimed |
| US-20020147200-A1 | Novel compounds and their use | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-10-10 | — | — | US | claimed |
| WO-2002040456-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2002-05-23 | — | — | WO | claimed |
| EP-1335907-B1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB PUBL (SE) | 2010-06-09 | — | — | EP | disclosed |
| US-7247633-B2 | Pyrimidine compounds and their use | BIOVITRUM AB (SE) | 2007-07-24 | — | — | US | disclosed |
| US-20040014767-A1 | Novel compounds and their use | BIOVITRUM AB, A SWEDISH CORPORATION | 2004-01-22 | — | — | US | disclosed |
| EP-1335907-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2003-08-20 | — | — | EP | disclosed |
| US-6593330-B2 | Central nervous system disorders; antiserotonine agents | BIOVITRUM (SE) | 2003-07-15 | — | — | US | disclosed |
| US-20020147200-A1 | Novel compounds and their use | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-10-10 | — | — | US | disclosed |
| WO-2002040456-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147200-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | HTR2C 916/4885HTR2A 1308/4885HTR1A 611/4885 |
| US-20040014767-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | HTR2C 916/4885HTR2A 1308/4885HTR1A 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.